Tepadina Injection
Generic name:thiotepa
Dosage form: injection, powder, for solution
Drug class:Alkylating agents
Medically reviewed by Drugs.com. Last updated on Feb 21, 2022.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Clinical Studies
- Nonclinical Toxicology
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY
- TEPADINA may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of TEPADINA [see Warnings and Precautions (5.1)]
- TEPADINA should be considered potentially carcinogenic in humans [see Warnings and Precautions (5.7)]
Indications and Usage for Tepadina Injection
Class 3 Beta-Thalassemia
TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies (14)].
Adenocarcinoma of the Breast or Ovary
TEPADINA is indicated for treatment of adenocarcinoma of the breast or ovary.
Malignant Effusions
TEPADINA is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
